BACKGROUND/AIMS To date, an effective salvage chemotherapy regimen for the treatment of refractory or relapsing non-Hodgkin's lymphoma (NHL) has not been discovered. This study was conducted to evaluate the efficacy and safety of gemcitabine, etoposide, cisplatin, and dexamethasone in relapsed or refractory NHL patients. METHODS All patients had histologically proven relapsed or refractory NH...

BACKGROUND Rituximab-containing salvage chemotherapy has shown promising efficacy in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). The aim of this study was to examine the efficacy of rituximab-containing treatment in patients with B-cell NHL who developed relapsed or refractory disease after prior rituximab use and to explore the predictive factors of response using th...

The optimal stem cell transplantation (SCT) conditioning therapy for relapsed/refractory nonHodgkin lymphoma (NHL) is not clearly defined. In a retrospective analysis, we examined 25 patients with “high risk” relapsed/refractory NHL who received busulfan, cyclophosphamide, and etoposide (Bu/Cy/VP16) conditioning with autologous or allogeneic SCT. The majority of patients had aggressive histolog...

MIL62 is a glycoengineered anti-CD20 antibody with nearly completely afucosylated N-glycans in Fc region that demonstrated superior activity comparison rituximab and obinutuzumab vitro vivo, respectively. Orelabrutinib (ICP-022) novel highly selective irreversible Bruton’s tyrosine kinase (BTK) inhibitor does not affect IL2-associated (ITK) or antibody-dependent cellular cytotoxicity, making it...

Introduction: While combination therapy is the standard of care for relapsed/ refractory non-Hodgkin lymphoma (RR-NHL), choice combinations an individual patient empirical, and response rates remain poor. Here we explore use a hybrid experimental/analytic method termed Quadratic Phenotypic Optimization Platform (QPOP), prediction optimal drug from limited clinical material. This high-throughput...

Primary testicular non-Hodgkin’s lymphoma (NHL) has a very low incidence. Therefore, clinical examination and imaging of testis is overlooked in the routine mapping NHL. We discuss case Waldeyer’s ring NHL who also had asymptomatic on presentation importance ultrasound workup.

Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over past two decades have strategically exploited lineage markers suitable for targeting by immunotherapies. First, addition anti-CD20 monoclonal antibody (mAb) rituximab to a range standard therapies conferred remarkable outcomes improvements diverse settings, perhaps most prominently an overall survival advantage ne...

Previously obscured within other designations of aggressive lymphomas, peripheral T-cell lymphoma (PTCL) now represents 23 different subtypes of non-Hodgkin lymphoma (NHL). Despite the many subtypes now recognized, PTCL represents only approximately 10% of all NHL cases diagnosed. Positron emission tomography/computed tomography has become essential to accurate staging and response-evaluation f...

Radioimmunotherapy of indolent non-Hodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is relatively underused in routine practice. In this article, we report our clinical experience in 142 consecutive patients who received iodine-131 rituximab radioim...

Abstract Introduction: Extra-nodal exposition of T-cell non-hodgkin lymphoma (NHL) is extremely rare, and is frequently observed in patients with immune system dysfunction. Peripheral T-cell lymphoma does not express CD56 is rare. Malignant lymphoma of the uvula is exceedingly unusual. The current study reported a case of peripheral T-cell lymphoma of the uvula in an immunecompetent patient. ...